Abstract
The FDA approvals of siponimod and cladribine for secondary progressive multiple sclerosis raise questions about the diagnostic criteria for multiple sclerosis phenotypes and their applicability to clinical trials. A simpler classification for the disease could be the answer.
Original language | English (US) |
---|---|
Pages (from-to) | 431-432 |
Number of pages | 2 |
Journal | Nature Reviews Neurology |
Volume | 15 |
Issue number | 8 |
DOIs |
|
State | Published - Aug 1 2019 |
ASJC Scopus subject areas
- Clinical Neurology
- Cellular and Molecular Neuroscience